WORLD NEWS
-
Sino Biopharm buys LaNova Medicines for US$951M to strengthen cancer therapy portfolio
The net payment for the acquisition will be approximately US$501 million, as this figure excludes LaNova’s estimated cash and bank deposits of around US$450 million.
-
Gavi reports historic gains in global immunization, protecting record 72 million children in 2024
Gavi’s broader goal of protecting 1.1 billion children by 2025 has already been surpassed, with 1.2 billion children protected since 2000.
-
Evonik opens largest medical device center in Shanghai to serve Asia
This state-of-the-art facility focuses on the research, development, and manufacturing of semi-finished components used in bioresorbable medical devices.
-
Brenntag to expand availability of Budenheim phosphate-based excipients across Europe
Budenheim’s range of phosphate-based excipients stands out for its unique high bulk density, which enables companies to manufacture smaller tablets without compromising mechanical integrity.
-
-
Waters Corporation to acquire BD Biosciences & Diagnostics in US$17.5B deal
This divestiture is part of BD’s five-year plan to sharpen its focus on core medical supplies and drug delivery technologies.
-
Wockhardt exits US Generics to fuel Innovation in antibiotics manufacturing
This decision took effect on July 11, 2025, and allows for a clean and structured exit from a legacy business segment, freeing up capital and management focus on antibiotic and insulin manufacturing
-
FDA rejection delays Ultragenyx’s gene therapy for rare neurological disease
In a Complete Response Letter (CRL) sent to Ultragenyx, the FDA cited manufacturing-related concerns tied to facility processes and practices observed during inspections.
-
Novartis gains approval for infant-specific Coartem Baby
Novartis plans to introduce Coartem Baby primarily on a not-for-profit basis to improve access in malaria-endemic regions, reflecting its long-term commitment to fighting malaria.
-
J&J seeks expanded EU approval for Akeega in prostate cancer
Johnson & Johnson aims extend Akeega’s approval to include patients with metastatic hormone-sensitive prostate cancer (mHSPC) who have homologous recombination repair (HRR) gene alterations.